{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:11:06Z","timestamp":1771513866664,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04041-6","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T18:19:36Z","timestamp":1757528376000},"page":"841-849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-5450","authenticated-orcid":false,"given":"Miguel Angel","family":"Berenguer-Frances","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrahams","family":"Ocanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Lopez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Celada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Gomez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"4041_CR1","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al. Randomized phase 3 noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325\u201332.","journal-title":"J Clin Oncol"},{"key":"4041_CR2","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884\u201390.","journal-title":"J Clin Oncol"},{"key":"4041_CR3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047\u201360.","journal-title":"Lancet Oncol"},{"key":"4041_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","volume":"100","author":"IR Vogelius","year":"2018","unstructured":"Vogelius IR, Bentzen SM. Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys. 2018;100:858\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4041_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.brachy.2009.12.004","volume":"10","author":"T Pickles","year":"2011","unstructured":"Pickles T, Morris WJ, Kattan MW, Yu C, Keyes M. Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. Brachytherapy. 2011;10(1):9\u201314.","journal-title":"Brachytherapy"},{"issue":"12","key":"4041_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","volume":"32","author":"JB Yu","year":"2014","unstructured":"Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol. 2014;32(12):1195\u2013201.","journal-title":"J Clin Oncol"},{"key":"4041_CR7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2019.12.023","volume":"145","author":"JA Halpern","year":"2020","unstructured":"Halpern JA, Sedrakyan A, Hsu WC, Hsu WC, Mao J, Schaeffer EM, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Radiother Oncol. 2020;145:95\u2013100.","journal-title":"Radiother Oncol"},{"key":"4041_CR8","first-page":"685","volume":"160","author":"SA Grover","year":"1999","unstructured":"Grover SA, Zowall H, Coupal L, Krahn MD. Prostate cancer: 12. The economic burden. CMAJ. 1999;160:685\u201390.","journal-title":"CMAJ"},{"issue":"1","key":"4041_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","volume":"11","author":"Y Yamada","year":"2012","unstructured":"Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy. 2012;11(1):20\u201332.","journal-title":"Brachytherapy"},{"key":"4041_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semradonc.2019.08.003","volume":"30","author":"J Crook","year":"2020","unstructured":"Crook J, Marban M, Batchelar D. HDR prostate brachytherapy. Semin Radiat Oncol. 2020;30:49\u201360.","journal-title":"Semin Radiat Oncol"},{"key":"4041_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.radonc.2020.01.025","volume":"146","author":"A Gomez-Iturriaga","year":"2020","unstructured":"Gomez-Iturriaga A, Buchser D, Mayrata E, San Miguel I, Gonzalez A, Suarez F, et al. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial. Radiother Oncol. 2020;146:16\u201320.","journal-title":"Radiother Oncol"},{"key":"4041_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.brachy.2011.05.003","volume":"11","author":"PJ Prada","year":"2012","unstructured":"Prada PJ, Jimenez I, Gonzalez-Suarez H, Fernandez J, Cuervo-Arango C, Mendez L. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy. 2012;11:105\u201310.","journal-title":"Brachytherapy"},{"key":"4041_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.radonc.2020.09.007","volume":"154","author":"Y Alayed","year":"2021","unstructured":"Alayed Y, Loblaw A, McGuffin M, Chung HT, Tseng CL, D\u2019Alimonte L, et al. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: outcomes from two clinical trials with and without an MRI-guided boost. Radiother Oncol. 2021;154:29\u201335.","journal-title":"Radiother Oncol"},{"key":"4041_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","volume":"146","author":"G Morton","year":"2020","unstructured":"Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol. 2020;146:90\u20136.","journal-title":"Radiother Oncol"},{"key":"4041_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.radonc.2020.12.021","volume":"156","author":"M Corkum","year":"2021","unstructured":"Corkum M, Loblaw A, Hasan Y, Chung HT, Tseng CL, McGuffin M, et al. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiother Oncol. 2021;156:160\u20135.","journal-title":"Radiother Oncol"},{"key":"4041_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110426","volume":"199","author":"P Hoskin","year":"2024","unstructured":"Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G. Single-dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer. Radiother Oncol. 2024;199:110426.","journal-title":"Radiother Oncol"},{"key":"4041_CR17","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer; 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"4041_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2019.03.002","volume":"135","author":"Y Alayed","year":"2019","unstructured":"Alayed Y, Cheung P, Chu W, Chung H, Davidson M, Ravi A, et al. Two stereotactic ablative radiotherapy treatments for localized prostate cancer (2STAR): results from a prospective clinical trial. Radiother Oncol. 2019;135:86\u201390.","journal-title":"Radiother Oncol"},{"issue":"1","key":"4041_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12885-024-12165-1","volume":"24","author":"E Fredman","year":"2024","unstructured":"Fredman E, Icht O, Moore A, Bragilovski D, Kindler J, Golan S, et al. SABR-dual: a phase II\/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer. BMC Cancer. 2024;24(1):431.","journal-title":"BMC Cancer"},{"key":"4041_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1186\/s12885-023-11430-z","volume":"23","author":"S Wolfe","year":"2023","unstructured":"Wolfe S, Diven MA, Marciscano AE, et al. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT). BMC Cancer. 2023;23:923.","journal-title":"BMC Cancer"},{"issue":"3","key":"4041_CR21","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","volume":"118","author":"RL Westley","year":"2024","unstructured":"Westley RL, Biscombe K, Dunlop A, Mitchell A, Oelfke U, Nill S, et al. Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging-guided adaptive prostate radiation therapy. Int J Radiat Oncol Biol Phys. 2024;118(3):682\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"4041_CR22","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ijrobp.2024.06.038","volume":"120","author":"E Fredman","year":"2024","unstructured":"Fredman E, Moore A, Icht O, Tschernichovsky R, Shemesh D, Bragilovski D, et al. Acute toxicity and early prostate specific antigen response after two-fraction stereotactic radiation therapy for localized prostate cancer using peri-rectal spacing: initial report of the SABR-Dual trial. Int J Radiat Oncol Biol Phys. 2024;120(5):1404\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"4041_CR23","first-page":"00298","volume":"S2588\u20139311","author":"C Udovicich","year":"2025","unstructured":"Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, et al. Two-fraction versus five-fraction stereotactic body radiotherapy for intermediate-risk prostate cancer: the TOFFEE meta-analysis of individual patient data from four prospective trials. Eur Urol Oncol. 2025;S2588\u20139311(24):00298.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"4041_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","volume":"7","author":"C Greco","year":"2021","unstructured":"Greco C, Pares O, Pimentel N, Louro V, Santiago I, Vieira S, et al. Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial. JAMA Oncol. 2021;7(5):700\u20138.","journal-title":"JAMA Oncol"},{"key":"4041_CR25","doi-asserted-by":"publisher","first-page":"11018","DOI":"10.1016\/j.radonc.2024.110181","volume":"194","author":"T Zilli","year":"2024","unstructured":"Zilli T, Franzese C, Guckenberger M, Giaj-Levra N, Mach N, Koutsouvelis N, et al. ONE SHOT\u2013single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I\/II trial. Radiother Oncol. 2024;194:11018.","journal-title":"Radiother Oncol"},{"issue":"5","key":"4041_CR26","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.ijrobp.2024.06.030","volume":"120","author":"S Arcangeli","year":"2024","unstructured":"Arcangeli S, Chissotti C, Ferrario F, Lucchini R, Belmonte M, Purrello G, et al. Ablative radiation therapy for unfavorable prostate tumors (ABRUPT): preliminary analysis of toxicity and quality of life from a prospective study. Int J Radiat Oncol Biol Phys. 2024;120(5):1394\u2013403.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4041_CR27","unstructured":"Kishan AU, Lamb JM, Wilhalme H, Casado M, Chong N, Zello L, et al. Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial. Eur Urol. 2024:S0302-2838(24)02688-5."},{"key":"4041_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1337626","volume":"13","author":"J Kim","year":"2023","unstructured":"Kim J, Sung J, Lee SJ, Cho KS, Chung BH, Yang D, et al. Optimal planning target margin for prostate radiotherapy based on interfractional and intrafractional variability assessment during 1.5T MRI-guided radiotherapy. Front Oncol. 2023;13:1337626.","journal-title":"Front Oncol"},{"key":"4041_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.radonc.2021.03.018","volume":"159","author":"S Armstrong","year":"2021","unstructured":"Armstrong S, Brown S, Stancliffe M, et al. Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: mature results of a phase 2 clinical trial. Radiother Oncol. 2021;159:67\u201374.","journal-title":"Radiother Oncol"},{"issue":"6","key":"4041_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.brachy.2018.06.002","volume":"17","author":"PJ Prada","year":"2018","unstructured":"Prada PJ, Ferri M, Cardenal J, Blanco AG, Anchuelo J, D\u00edaz de Cerio I, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: toxicity and 6-year biochemical results. Brachytherapy. 2018;17(6):845\u201351.","journal-title":"Brachytherapy"},{"issue":"2","key":"4041_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.radonc.2018.03.022","volume":"127","author":"G Nagore","year":"2018","unstructured":"Nagore G, Lopez Guerra JL, Krumina E, Lagos M, Ovalles B, Mir\u00f3 A, et al. High dose rate brachytherapy for prostate cancer: a prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions. Radiother Oncol. 2018;127(2):219\u201324.","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04041-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04041-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04041-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:19:29Z","timestamp":1771510769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04041-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4041"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04041-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}